TY  - JOUR
TI  - Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib
AB  - OBJECTIVE We investigated the relationship of baseline sarcopenia with toxicities, treatment response, and survival in patients who had non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation and received erlotinib. METHODS Computed tomography images from PET/CT scans before erlotinib treatment were retrospectively as- sessed. Skeletal muscle index, calculated as skeletal muscle area at third lumbar vertebra level/square of height, was used to define sarcopenia with <52.4 cm 2/m2 for males and <38.5 cm 2/m2 for females. Cox hazard models were conducted to determine predictors of survival. RESULTS The study included 30 patients, and 11 (36.7%) were sarcopenic. All-grade and Grade 3 toxicities were more frequent in sarcopenic group, although it was statistically insignificant (81.8% vs. 63.2%, p=0.282 for all-grade, and 18.2% vs. 10.5%, p=0.552 for grade 3). Response rates were 63.6% in sar- copenic and 68.4% in non-sarcopenic patients (p=0.789). Median progression-free survival was 7.9 and 9.2 months in sarcopenic and non-sarcopenic cases, respectively (p=0.561). However, median overall survival (OS) of sarcopenic patients was significantly shorter than non-sarcopenic ones (11.8 vs. 30.2 months, p=0.023), and sarcopenia predicted OS independently in multivariate analysis (Hazard ratio=2.63, p=0.029). CONCLUSION Early recognition, treatment, and prevention of sarcopenia may improve long-term survival in EGFR- mutant NSCLC patients treated with first-line erlotinib.
AU  - Özgüven, Salih
AU  - ARIKAN, RUKİYE
AU  - çelebi, abdussamet
AU  - Alan, Ozkan
AU  - ışık, selver
AU  - Ercelep, Özlem
AU  - Dane, Faysal
AU  - Akın Telli, Tugba
AU  - Yasar, Alper
AU  - Engur, Ceren Ozge
AU  - Basoglu tuylu, Tugba
AU  - Demircan, Nazım Can
AU  - Kaya, Handan
AU  - Ones, Tunc
AU  - Yumuk, Perran Fulden
DO  - 10.5505/tjo.2022.3547
PY  - 2022
JO  - Türk Onkoloji Dergisi
VL  - 37
IS  - 4
SN  - 1300-7467
SP  - 379
EP  - 387
DB  - TRDizin
UR  - http://search/yayin/detay/1175700
ER  -